Graph Therapeutics
Vienna
About Graph Therapeutics
Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are left without adequate treatment options - and AI trained with complex disease data can solve this.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $4.4M
- Funding stage: Seed
- Last round: Pre-Seed (Jan 2025)
- Website: graphtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/graph-therapeutics-10053 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.